A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
=== Axon growth regulation === Crosslinking anti-Thy-1 Ab can promote neurite outgrowth which is dependent on G{alpha}i and L- and N-type calcium channel activation. The ligand for promotion of neurite outgrowth on astrocytes is not yet identified, but the inhibitory ligand has been suggested to be integrins. Thy1 is one of the known ligands of beta 3 integrins. Interaction of thy1 expressed on maturing axons with beta 3 integrins expressed on mature astrocytes is one of the causes of halting of axon growth.
=== Stability === "LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule ... As a salt, in water, cold, and free from air and light exposure, it is stable indefinitely." LSD has two labile protons at the tertiary stereogenic C5 and C8 positions, rendering these centers prone to epimerisation. The C8 proton is more labile due to the electron-withdrawing carboxamide attachment, but the removal of the chiral proton at the C5 position (which was once also an alpha proton of the parent molecule tryptophan) is assisted by the inductively withdrawing nitrogen and pi electron delocalisation with the indole ring. LSD also has enamine-type reactivity because of the electron-donating effects of the indole ring. Because of this, chlorine destroys LSD molecules on contact; even though chlorinated tap water contains only a slight amount of chlorine, the small quantity of compound typical to an LSD solution will likely be eliminated when dissolved in tap water. The double bond between the 8-position and the aromatic ring, being conjugated with the indole ring, is susceptible to nucleophilic attacks by water or alcohol, especially in the presence of UV or other kinds of light. LSD often converts to lumi-LSD (10-hydroxy-9,10-dihydro-LSD), which is inactive in human beings. A controlled study was undertaken to determine the stability of LSD in pooled urine samples.
== Metrics == The following are the most commonly measured pharmacokinetic metrics: The units of the dose in the table are expressed in moles (mol) and molar (M). To express the metrics of the table in units of mass, instead of amount of substance, simply replace 'mol' with 'g' and 'M' with 'g/L'. Similarly, other units in the table may be expressed in units of an equivalent dimension by scaling.
Sources: en.wikipedia.org
As of 2017, the Panda Restaurant Group had annual sales of over $3 billion and close to 39,000 employees. The Cherngs also opened Panda Innovation Kitchen in Pasadena with their daughter, Andrea Cherng, overlooking a majority of the restaurant's business. The idea for Panda Innovation Kitchen is to experiment with new flavours and ingredients to come up with new menu items. In addition, they also opened a tea bar to introduce Taiwanese drinks such as boba milk tea and new drinks like the Fortune Cookie Shake.In December 2017, Panda Express had opened the chain's 2,000th location, which is located in New York City near Columbia University. In February 2022, Panda Restaurant Group filed a U.S. trademark application for the name PANDAVERSE for "downloadable virtual goods, namely, food items and beverages for use in virtual worlds" and "virtual food and beverage products." The filing marked an intention to expand the Panda Express brand into the Metaverse. In March 2022, Panda Express committed to transitioning to 100% cage-free eggs, responding to pressure from animal welfare groups.
2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency. Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine (EC50 = >100,000 nM or "inactive"). 2C-B shows dopaminergic actions mediated by the dopamine transporter (DAT) in monkeys but not in rodents. 2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It shows reinforcing effects in monkeys but not in rodents. The drug also shows potent and efficacious anti-inflammatory effects in preclinical research. In contrast to MDMA, which robustly increases oxytocin levels and produces associated entactogenic effects, 2C-B minimally affects oxytocin levels in humans.
Naturally occurring tellurium on Earth consists of eight isotopes: 120, 122-126, 128, 130. The heaviest two have been found to be radioactive: 128Te and 130Te undergo double beta decay with half-lives of, respectively, 7.7×1024 years (the longest half-life of all nuclides proven to be radioactive) and 7.9×1020 years. Artificial radioisotopes of tellurium are known, with atomic masses that range from 104 to 142, of which the most stable is 121Te with a half-life of 19.31 days. Several nuclear isomers have longer half-lives, the longest being 121mTe with a half-life of 164.7 days. The very long-lived radioisotopes 128Te and 130Te are the two most common isotopes of tellurium. Of elements with at least one stable isotope, only indium and rhenium likewise have a radioisotope in greater abundance than a stable one. It has been claimed that electron capture of 123Te was observed, but more recent measurements of the same team have disproved this. They have determined the half-life of 123Te to be longer than 9.2 × 1016 years (or 2 × 1015 years without any theoretical assumptions). Its observational stability presents one of only two apparent violations of the Mattauch isobar rule, the other involving 180mTa. 124Te is used as the starting material in the production of certain radionuclides by a cyclotron or other particle accelerator, such as iodine-123 and iodine-124. With the exception of beryllium, tellurium is the lightest element observed to have isotopes capable of undergoing alpha decay, with isotopes 104Te to 109Te being seen to undergo this mode of decay.
Sources: en.wikipedia.org
==== Renal filtration, reabsorption, and excretion ==== Potassium ions are reabsorbed from blood plasma entering the glomeruli into the renal tubule of the kidneys. Only a small amount of potassium reaches the distal nephron. Renal handling of potassium is closely connected to sodium handling. Potassium is the major cation (positive ion) inside animal cells (150 mmol/L, 4.8 g/L), while sodium is the major cation of extracellular fluid (150 mmol/L, 3.345 g/L). In the kidneys, about 180 liters of plasma is filtered through the glomeruli and into the renal tubules per day. Sodium is reabsorbed to maintain extracellular volume, osmotic pressure, and serum sodium concentration within narrow limits. Potassium is reabsorbed to maintain serum potassium concentration within narrow limits. Sodium pumps in the renal tubules operate to reabsorb sodium. Potassium must be conserved, but because the amount of potassium in the blood plasma is very small and the pool of potassium in the cells is about 30 times as large, the situation is not so critical for potassium. Since potassium is moved passively in counter flow to sodium in response to an apparent (but not actual) Donnan equilibrium, the urine can never sink below the concentration of potassium in serum except sometimes by actively excreting water at the end of the processing. Potassium is excreted twice and reabsorbed three times before the urine reaches the collecting tubules.
=== Triphasic bonds === Other type of "dynamic bonds" have been defined in addition to the original types of catch bonds, slip bonds and ideal bonds classified by Dembo. Unlike slip bonds, which have been observed in the entire force range tested, catch bonds only exist within certain force range as any molecular bond would eventually be overpowered by high enough force. Therefore, catch bonds are always followed by slip bonds, hence termed "catch-slip bonds". More variations have also been observed, e.g., triphasic slip-catch-slip bonds.
The scandal began with revelations of contamination of Sanlu milk products. The New Zealand dairy cooperative Fonterra, which owned a 43% stake in Sanlu, said they were alerted to melamine contamination on 2 August (almost a month before the issue became public), and have said to have pushed hard for a full public recall. Although there was an immediate trade recall, Fonterra said that local administrators refused an official recall. A Fonterra director had given Sanlu management a document detailing the European Union's permitted levels of melamine, but Fonterra chief executive Andrew Ferrier has stated that at no time did Fonterra say small amounts of melamine were acceptable.
== Treatment == Treatment for LNS is symptomatic. Gout can be treated with allopurinol to control excessive amounts of uric acid. Kidney stones may be treated with lithotripsy, a technique for breaking up kidney stones using shock waves or laser beams. There is no standard treatment for the neurological symptoms of LNS. Some may be relieved with the drugs carbidopa/levodopa, diazepam, phenobarbital, or haloperidol. It is essential that the overproduction of uric acid be controlled in order to reduce the risk of nephropathy, nephrolithiasis, and gouty arthritis. The drug allopurinol is utilized to stop the conversion of oxypurines into uric acid, and prevent the development of subsequent arthritic tophi (produced after having chronic gout), kidney stones, and nephropathy, the resulting kidney disease. Allopurinol is taken orally, at a typical dose of 3–20 mg/kg per day. The dose is then adjusted to bring the uric acid level down into the normal range (<3 mg/dL). Most affected individuals can be treated with allopurinol all through life. No medication is effective in controlling the extrapyramidal motor features of the disease. Spasticity, however, can be reduced by the administration of baclofen or benzodiazepines. There has previously been no effective method of treatment for the neurobehavioral aspects of the disease. Even children treated from birth with allopurinol develop behavioral and neurologic problems, despite never having had high serum concentrations of uric acid.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.